YU61200A - Derivati hinolina - Google Patents
Derivati hinolinaInfo
- Publication number
- YU61200A YU61200A YU61200A YU61200A YU61200A YU 61200 A YU61200 A YU 61200A YU 61200 A YU61200 A YU 61200A YU 61200 A YU61200 A YU 61200A YU 61200 A YU61200 A YU 61200A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- propyl
- iso
- butyl
- formula
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Ovaj pronalazak se odnosi na jedinjenje opšte formule (I) gde se R bira izmedju etil, n-propil, izo-propil, sek-butil i alil; R4 se bira izmedju vodonika ili farmaceutski prihvatljivog neorganskog ili organskog kationa R se bira izmedju metil, etil, n-propil, izo-propil, metoksi, etoksi, hloro, bromo, CF3 ili OCHxFy; pri čemu je X= 0 do 2, y = 1 do 3 uz uslov da je x+y=3; R6 je vodonik, ili R5 i R6 uzeti zajedno su metilendioksi; i njihov bilo koji tautomer. Ovaj pronalazak se takodje odnosi na farmaceutske preparate koji sadrže jedinjenje opšte formule (I), zajedno sa farmaceutski prihvatljivim nosačem. Takodje su uključeni i postupci za dobijanje jedinjenja formule (I).[The invention relates to compounds of general formula (I) wherein R is selected from ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl and allyl; R4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R5 is selected from methyl, ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, CF3, and OCHxFy; wherein x = 0 - 2, y = 1 - 3 with the proviso that x + y = 3; R6 is hydrogen; or R5 and R6 taken together are methylenedioxy; and any tautomer thereof. The invention also relates to pharmaceutical compositions containing a compound of general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods of treating mammals suffering from diseases resulting from autommunity and pathological inflammation by administrering a compound having formula (I) to said mammal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801474A SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Quinoline Derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU61200A true YU61200A (sh) | 2003-07-07 |
| RS50029B RS50029B (sr) | 2008-11-28 |
Family
ID=20411103
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1073639B1 (sh) |
| JP (1) | JP4045069B2 (sh) |
| KR (1) | KR100571534B1 (sh) |
| CN (1) | CN1113057C (sh) |
| AP (1) | AP1293A (sh) |
| AT (1) | ATE228505T1 (sh) |
| AU (1) | AU747550B2 (sh) |
| BR (1) | BR9909925B1 (sh) |
| CA (1) | CA2329788C (sh) |
| CZ (1) | CZ297439B6 (sh) |
| DE (1) | DE69904162T2 (sh) |
| DK (1) | DK1073639T3 (sh) |
| EE (1) | EE04275B1 (sh) |
| ES (1) | ES2188242T3 (sh) |
| HK (1) | HK1036618A1 (sh) |
| HR (1) | HRP20000726B1 (sh) |
| HU (1) | HU227709B1 (sh) |
| ID (1) | ID26277A (sh) |
| IL (2) | IL138160A0 (sh) |
| IS (1) | IS2082B (sh) |
| ME (1) | ME00870B (sh) |
| NO (1) | NO315606B1 (sh) |
| NZ (1) | NZ506641A (sh) |
| OA (1) | OA11547A (sh) |
| PL (1) | PL190441B1 (sh) |
| PT (1) | PT1073639E (sh) |
| RS (1) | RS50029B (sh) |
| RU (1) | RU2197481C2 (sh) |
| SE (1) | SE9801474D0 (sh) |
| TR (1) | TR200003061T2 (sh) |
| UA (1) | UA60354C2 (sh) |
| WO (1) | WO1999055678A1 (sh) |
| ZA (1) | ZA200004601B (sh) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| KR100908655B1 (ko) | 2002-11-27 | 2009-07-21 | 엘지디스플레이 주식회사 | 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치 |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
| US7973039B2 (en) | 2004-12-21 | 2011-07-05 | Merck Serono Sa | Sulfonyl amino cyclic derivatives and use thereof |
| BRPI0606756A2 (pt) | 2005-01-31 | 2009-07-14 | Serono Lab | derivados de n-hidroxiamida e uso do mesmo |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| AU2006286489B2 (en) | 2005-09-01 | 2012-08-09 | Ares Trading S.A. | Treatment of optic neuritis |
| ES2523762T3 (es) | 2005-10-19 | 2014-12-01 | Teva Pharmaceutical Industries Ltd | Cristales de laquinimod sódico, y procedimientos para su fabricación |
| RS52169B (en) | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | STABLE LAKVINIMOD PREPARATIONS |
| PL2682120T3 (pl) | 2007-12-20 | 2017-02-28 | Teva Pharmaceutical Industries, Ltd. | Stabilne preparaty lakwinimodu |
| ES2633658T3 (es) * | 2008-09-03 | 2017-09-22 | Teva Pharmaceutical Industries Ltd. | Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria |
| DK2458992T3 (en) * | 2009-07-30 | 2016-02-08 | Teva Pharma | Treatment of crohn's disease with laquinimod |
| SI2467372T1 (sl) | 2009-08-10 | 2016-09-30 | Teva Pharmaceutical Industries Ltd. | Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda |
| SG10201501539SA (en) * | 2010-03-03 | 2015-04-29 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
| PE20130613A1 (es) * | 2010-03-03 | 2013-06-23 | Teva Pharma | Tratamiento de lupus nefritis usando laquinimod |
| EP2542079B1 (en) | 2010-03-03 | 2014-05-21 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| WO2011116091A1 (en) | 2010-03-17 | 2011-09-22 | Novartis Ag | Dispenser |
| CN102985090B (zh) * | 2010-07-09 | 2014-11-26 | 泰华制药工业有限公司 | 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途 |
| AU2011274496B2 (en) * | 2010-07-09 | 2016-03-10 | Teva Pharmaceutical Industries Ltd. | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| CN103119023B (zh) * | 2010-07-09 | 2014-12-24 | 活跃生物技术有限公司 | 生产喹啉-3-羧酰胺的改进方法 |
| EP2444086A1 (en) | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinations comprising DHODH inhibitors and COX inhibitors |
| JP2014530821A (ja) | 2011-10-12 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療 |
| EA201491460A1 (ru) * | 2012-02-03 | 2015-01-30 | Тева Фармасьютикал Индастриз Лтд. | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
| RU2545056C2 (ru) * | 2012-12-10 | 2015-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) | Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты |
| BR112015019564A2 (pt) * | 2013-02-15 | 2017-07-18 | Teva Pharma | tratamento de esclerose múltipla com laquinimod |
| TW201519892A (zh) | 2013-03-14 | 2015-06-01 | Teva Pharma | 拉喹莫德鈉之結晶及其製造之改良方法 |
| CN106573014A (zh) | 2014-04-29 | 2017-04-19 | 梯瓦制药工业有限公司 | 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| CA2961978C (en) | 2014-09-23 | 2023-03-14 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
| CA2967112C (en) | 2014-11-19 | 2023-05-16 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of leukemia |
| AU2020408179A1 (en) | 2019-12-19 | 2022-06-30 | Active Biotech Ab | Compounds for treatment of eye diseases associated with excessive vascularisation |
| JP2023519153A (ja) | 2020-03-03 | 2023-05-10 | アクティブ バイオテック エイビー | 組合せ療法における使用のためのタスキニモドまたはその薬学的に許容される塩 |
| US20230203003A1 (en) * | 2020-05-21 | 2023-06-29 | Stemsynergy Therapeutics, Inc. | Notch Inhibitors and Uses Thereof |
| EP4185292A1 (en) | 2020-07-23 | 2023-05-31 | Erasmus University Rotterdam Medical Center | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| JP2024503372A (ja) | 2021-01-18 | 2024-01-25 | アクティブ バイオテック エイビー | 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 |
| AU2022281056A1 (en) | 2021-05-25 | 2023-11-30 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
| EP4363404A1 (en) | 2021-07-02 | 2024-05-08 | Active Biotech AB | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-04-27 SE SE9801474A patent/SE9801474D0/xx unknown
-
1999
- 1999-04-26 PL PL99343420A patent/PL190441B1/pl unknown
- 1999-04-26 EE EEP200000613A patent/EE04275B1/xx unknown
- 1999-04-26 TR TR2000/03061T patent/TR200003061T2/xx unknown
- 1999-04-26 UA UA2000085078A patent/UA60354C2/uk unknown
- 1999-04-26 CZ CZ20003849A patent/CZ297439B6/cs not_active IP Right Cessation
- 1999-04-26 ES ES99947036T patent/ES2188242T3/es not_active Expired - Lifetime
- 1999-04-26 IL IL13816099A patent/IL138160A0/xx active IP Right Grant
- 1999-04-26 DE DE69904162T patent/DE69904162T2/de not_active Expired - Lifetime
- 1999-04-26 HU HU0102084A patent/HU227709B1/hu not_active IP Right Cessation
- 1999-04-26 AP APAP/P/2000/001933A patent/AP1293A/en active
- 1999-04-26 CA CA002329788A patent/CA2329788C/en not_active Expired - Fee Related
- 1999-04-26 AT AT99947036T patent/ATE228505T1/de active
- 1999-04-26 PT PT99947036T patent/PT1073639E/pt unknown
- 1999-04-26 KR KR1020007011944A patent/KR100571534B1/ko not_active IP Right Cessation
- 1999-04-26 EP EP99947036A patent/EP1073639B1/en not_active Expired - Lifetime
- 1999-04-26 ME MEP-2000-612A patent/ME00870B/me unknown
- 1999-04-26 DK DK99947036T patent/DK1073639T3/da active
- 1999-04-26 RS YUP-612/00A patent/RS50029B/sr unknown
- 1999-04-26 JP JP2000545838A patent/JP4045069B2/ja not_active Expired - Lifetime
- 1999-04-26 ID IDW20002183A patent/ID26277A/id unknown
- 1999-04-26 RU RU2000129672/04A patent/RU2197481C2/ru not_active IP Right Cessation
- 1999-04-26 CN CN99805581A patent/CN1113057C/zh not_active Expired - Fee Related
- 1999-04-26 NZ NZ506641A patent/NZ506641A/en not_active IP Right Cessation
- 1999-04-26 OA OA1200000301A patent/OA11547A/en unknown
- 1999-04-26 BR BRPI9909925-0A patent/BR9909925B1/pt not_active IP Right Cessation
- 1999-04-26 AU AU43013/99A patent/AU747550B2/en not_active Ceased
- 1999-04-26 WO PCT/SE1999/000676 patent/WO1999055678A1/en active IP Right Grant
-
2000
- 2000-08-30 IL IL138160A patent/IL138160A/en not_active IP Right Cessation
- 2000-08-31 IS IS5615A patent/IS2082B/is unknown
- 2000-09-01 ZA ZA200004601A patent/ZA200004601B/en unknown
- 2000-10-19 NO NO20005254A patent/NO315606B1/no not_active IP Right Cessation
- 2000-10-26 HR HR20000726A patent/HRP20000726B1/xx not_active IP Right Cessation
-
2001
- 2001-08-07 HK HK01105489A patent/HK1036618A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU61200A (sh) | Derivati hinolina | |
| YU1501A (sh) | Derivati hinolina | |
| AP1425A (en) | Quinoline derivatives. | |
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| ATE37179T1 (de) | Dihydropyridazinone. | |
| EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
| ATE139233T1 (de) | Annelierte thiophen-derivate, ihre herstellung und verwendung | |
| EE200100513A (et) | Rakkude adhesiooni inhibeerivad põletikuvastased ja immunosupressiivsed ühendid | |
| GB9310582D0 (en) | Pharmaceuticals | |
| MXPA03011954A (es) | Nuevos derivados de acido sulfonico. | |
| ES8802052A1 (es) | Un metodo para preparar derivados de 9-bencilpurina | |
| EA200101050A1 (ru) | Замещенные бензолактамные соединения | |
| ES8504707A1 (es) | Derivados del indol | |
| SE0400440D0 (sv) | Novel Cinnamic Amides | |
| AU6984600A (en) | 5-aminoalkyl and 5-aminocarbonyl substituted indoles | |
| FI834789A0 (fi) | Foerfarande foer framstaellning av 1,1-difenylpropanolderivat | |
| SE8405332L (sv) | 2h-azeto (2,1-a)-isokinolinderivat, forfarande for deras framstellning och farmaceutiska kompositioner innehallande dem | |
| TW430666B (en) | New 5H-thiazolo[3,2-a]pyrimidin-5-one derivatives | |
| TW200718699A (en) | Fused bicycloheterocycle substituted quinuclidine derivatives |